Exact Sciences closed 2025 with $3.25 billion in total revenue, marking an 18% year-over-year increase—fueled largely by its cancer screening portfolio, including stool-based colorectal cancer screening test Cologuard. Screening revenue reached $2.53 billion, reflecting continued uptake of non-invasive, at-home CRC testing among average-risk adults aged 45 and older. Since launch, Cologuard has been used more than 20 million times, highlighting growing patient and provider preference for guideline-supported alternatives to colonoscopy. The company is now expanding beyond stool-based diagnostics, having secured exclusive U.S. rights to Freenome’s blood-based colorectal cancer screening test—signaling a strategic move into multi-modal CRC detection. Meanwhile, next-generation platforms…
Author: Abhay Panchal
Endoscopic ultrasound (EUS) is moving past its traditional role as a diagnostic imaging and sampling tool toward enabling early disease detection, molecular profiling, and personalized treatment, according to a comprehensive review published in Gastroenterology. The review, led by Michael B. Wallace, MD, MPH, the Fred C. Andersen Professor of Medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic, Jacksonville, Fla., describes how new technologies and workflows spanning molecular assays, advanced needle designs, and artificial intelligence (AI) are redefining the diagnostic potential of EUS across gastrointestinal and hepatobiliary diseases. “In the past five years or so, there’s been a…
Infliximab (IFX) transformed inflammatory bowel disease (IBD) care when it was introduced as the first biologic therapy for Crohn’s disease and ulcerative colitis. Now, a subcutaneous (SC) formulation may represent the next evolution. A review of published evidence shows that SC infliximab achieves higher and more stable serum drug levels compared with intravenous (IV) administration, with fewer neutralizing antibodies and comparable remission rates. Real-world data suggest that switching stable patients from IV to SC IFX (120 mg) is well tolerated and associated with a low relapse risk. Beyond pharmacokinetics, SC IFX offers practical advantages: While SC infliximab supports a more…
In this episode of the Gut Doctor podcast, Dr. Parikh discusses the current treatment landscape of constipation with Dr. Satish Rao. Dr. Rao is Chair of Gastroenterology, Professor of Medicine, and Director of Neurogastroenterology and Motility at August University.
At Crohn’s & Colitis Congress 2026, a large Mayo Clinic real-world analysis (580 GLP-1–exposed patients) found that patients with ulcerative colitis and Crohn’s disease who used GLP-1s had: Compared with matched IBD patients not on GLP-1 therapy. This was an observational study — so no causality — but the consistency across both UC and Crohn’s suggests a potential anti-inflammatory signal. Bottom line: GLP-1s appear safe in IBD and may even confer benefit, particularly in patients with comorbid obesity or cardiometabolic disease. Prospective studies are needed before positioning them as adjunctive therapy.
The 2025 Identity Theft Resource Center report confirms what many physician-owners are feeling: cyberattacks are no longer random — they’re precise, automated, and increasingly targeted at healthcare. In 2025 alone: This is not “spray-and-pray” ransomware anymore. It’s strategic targeting of patient-record repositories — and private practices are high-value, lower-defense targets.
A recent analysis by healthcare innovation expert Jesse Pines, MD, examines whether the Galleri multi-cancer early detection (MCED) blood test lives up to its promise. Marketed as a simple blood draw capable of detecting over 50 cancers, Galleri analyzes cell-free DNA methylation patterns to identify a “cancer signal” and predict likely tissue of origin. The appeal is obvious: early detection without invasive screening. But the current evidence tells a more nuanced story.
Pathologists Aren’t a Black Box: Why GI–Pathology Communication Directly Impacts Patient Car In a compelling piece in GI & Hepatology News, Dr. Raul S. Gonzalez reminds gastroenterologists of something deceptively simple: pathologists are not diagnostic machines — they are consulting physicians. The article argues that better communication between gastroenterologists and GI pathologists can materially improve diagnostic accuracy, reduce ambiguity, and ultimately enhance patient outcomes. Key takeaways:
Gastroenterology is constantly evolving, with new technologies reshaping care delivery and access as well as the broader patient experience. From AI-driven detection and scheduling to advanced imaging and minimally invasive therapies, the following five innovations are improving outcomes while helping practices manage rising demand, staffing constraints and economic pressure.
Smart toilets are moving from concept to clinical infrastructure. In a recent conversation, Dr. Sonia Grego — Co-Founder & CEO of Coprata and Director of the Duke Smart Toilet Lab — discusses how passive stool analysis could unlock continuous, at-home health insights. Her work focuses on:• Biochemical biomarkers in stool• Sensor-based data capture in everyday settings• AI-driven interpretation• Shifting from episodic testing to longitudinal monitoring If realized at scale, platforms like this could redefine how we think about preventive GI and metabolic care. Worth a listen for anyone tracking the future of digital health and ambient diagnostics.